

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO	CONFIRMATION NO.
10/553,324	10/17/2005	Roger R. C. New	117-564	9059
23117 75	590 08/09/2006	EXAMINER		INER
NIXON & VANDERHYE, PC			KHANNA, HEMANT	
901 NORTH GLEBE ROAD, 11TH FLOOR ARLINGTON, VA 22203)K	ART UNIT	PAPER NUMBER
•			1654	
			DATE MAILED: 08/09/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
Office Action Summary	10/553,324	NEW, ROGER R. C.			
Onice Action Gammary	Examiner	Art Unit			
T. MANUS 0 4 TO	Hemant Khanna	1654			
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the o	correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be tir will apply and will expire SIX (6) MONTHS from 3. cause the application to become ABANDONE	N. mely filed the mailing date of this communication. ED (35 U.S.C. § 133).			
Status					
1)⊠ Responsive to communication(s) filed on <u>17 C</u>	October 2005				
<u> </u>	s action is non-final.				
, 	-				
closed in accordance with the practice under E					
Disposition of Claims	•				
4)⊠ Claim(s) <u>1-29</u> is/are pending in the application					
4a) Of the above claim(s) is/are withdraw					
5) Claim(s) is/are allowed.					
6) Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) 1-29 are subject to restriction and/or	election requirement.				
Application Papers	·				
9)☐ The specification is objected to by the Examine	A.F.				
10) The drawing(s) filed on is/are: a) acc		Evaminor			
Applicant may not request that any objection to the	•				
Replacement drawing sheet(s) including the correct		• •			
11) The oath or declaration is objected to by the Ex					
Priority under 35 U.S.C. § 119	diminor. Note the attached emoc	Action of 10mm 1 10-102.			
12) Acknowledgment is made of a claim for foreign	priority under 25 LLS C \$1400~	\			
a) ☐ All b) ☐ Some * c) ☐ None of:	priority under 35 0.5.C. § 119(a)-(a) or (i).			
1.☐ Certified copies of the priority document	s have been received				
2. Certified copies of the priority document		ion No			
3. Copies of the certified copies of the prior		· — —			
application from the International Bureau		su in this National Stage			
* See the attached detailed Office action for a list	• • • • • • • • • • • • • • • • • • • •	ed.			
	E. I. C. Colonia deploy not receive				
Attachment(s)					
1) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)			
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	ate			
 Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 	5) Notice of Informal F 6) Other:	Patent Application (PTO-152)			
· · · · · · · · · · · · · · · · · · ·	-,				

Application/Control Number: 10/553,324

Art Unit: 1654

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-16, drawn to a pharmaceutical composition comprising a mixture of an active macromolecular principle, aromatic absorption enhancer, and a solubilization aid.

Group II, claim(s) 17-27, drawn to use of an aromatic alcohol in the manufacture of a medicament.

Group III, claim(s) 28, drawn to a method of enhancing the absorption of an active macromolecular principle.

Group IV, claim(s) 29, drawn to a method of treating a patient suffering from a disease.

2. The inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the inventions lack the same or corresponding special technical features for the following reasons:

The MPEP states if an independent claim does not avoid the prior art, then the question whether there is still an inventive link between all the claims dependent on that claim needs to be carefully considered. Here the independent

claim, 1 is not free of the prior art. Together, New et al (WO 02/28436), and Wong et al (USPN 6,342,249) render obvious the claimed invention. While, New et al provide a pharmaceutical composition comprising a mixture of an active principle, aromatic alcohol, and a solubilization agent, Wong et al provide the use of butylated hydroxyl toluene, butylated hydroxyl anisole and analogues thereof.

3. This application contains claims 17-27 that provide for the use of the aromatic alcohol in the manufacture of a medicament, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. Further, the dependent claims 24-27 recite further limitations on the composition comprising the aromatic alcohol of the independent claim 17. Accordingly, claims 17-27 are being further treated on the merits as being drawn to the aromatic alcohol.

However if the applicant objects to the treatment of claims 17-27 as a product claim, the applicant can amend the claim and request that the claim be considered in one of the groups discussed above.

4. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

The macromolecular principle in claim 9, the aromatic alcohol absorption enhancers in claims 10-11, solubilization aids in claim 12, and other combinations of macromolecular principle, aromatic alcohol and solubilization aids not specifically recited in the claims.

5. The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: the shared technical feature is rendered obvious by New et al (WO 02/28436), and Wong et al (USPN 6,342,249).

Applicant is required, in reply to this action, to elect a single group and a single species encompassed by that group i.e., the macromolecular principle, aromatic alcohol absorption enhancer and solubilization aid must be defined specifically, to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by

37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Notice of Possible Rejoinder

6. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during

result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues.

See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Hemant Khanna whose telephone number is (571) 272-9045. The examiner can normally be reached on Monday through Friday, 7:30 am-4:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on (571) 272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

HK August 4, 2006